Moderna, Inc. has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). This filing is in accordance with Section 14(a) of the Securities Exchange Act of 1934, indicating that Moderna is preparing for upcoming corporate actions that require shareholder approval. The definitive proxy statement is a key document that outlines the agenda for the company's shareholder meeting, including matters such as election of directors, approval of compensation plans, and other significant corporate decisions. The document confirms that no filing fee is required for this submission.

Moderna, Inc. has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). This filing is in accordance with Section 14(a) of the Securities Exchange Act of 1934, indicating that Moderna is preparing for upcoming corporate actions that require shareholder approval. The definitive proxy statement is a key document that outlines the agenda for the company's shareholder meeting, including matters such as election of directors, approval of compensation plans, and other significant corporate decisions. The document confirms that no filing fee is required for this submission.